🚨Our work on long-term outcomes to PD-1 monotherapy by increasing PD-L1 levels in #NSCLC is out in JTO & JTO CRR.
PD-L1 TPS ≥90% (vs 50-89%) is associated w/⬆️3-year PFS and OS rates and favorable genomic & immunophenotypic profiles. #LCSM IASLC
tinyurl.com/333zumjd
🧵1/10

Very interesting study at ⁦Cancer Discovery⁩ Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced NSCLC Resistant to Immune Checkpoint Inhibitors aacrjournals.org/cancerdiscover…

Join our dream team 💭
Stephen V Liu, MD Charu Aggarwal, MD, MPH, FASCO Christine Lovly, MD, PhD So Yeon Kim Zosia Piotrowska I.DagogoJackMD Christine Bestvina
Ticiana Batista (Leal) Benjamin Levy Adam J. Schoenfeld Angel Qin

👉 Register now: ms.spr.ly/6010csMNM
#PLCClive24

Great way to end @aacr presenting our experience using MSK-IMPACT for HLA genotyping alongside rockstar fellow Antoine Desilets, MD, MSc at a session chaired by our amazing mentor Yonina Murciano-Goroff! Memorial Sloan Kettering Cancer Center #AACR24

Advancing the Fight Against Lung Cancer with TIL Therapy - Nicholas P Restifo
Adam J. Schoenfeld

#Cancer #Immunotherapy #LungCancer #OncoDaily #Oncology

oncodaily.com/45769.html

At #AACR24 , Mike V. Gormally, MD PhD will present the results of a study that identified novel T cell receptors in mouse xenograft models that have the potential to eliminate TP53-mutant tumors. Memorial Sloan Kettering Cancer Center
April 7 | 1:30 p.m. – 5 p.m. PT | Section 1
buff.ly/3TQwr4O

Want to learn more about prediction of immune checkpoint inhibitor cessation due to toxicities then stop by our poster on April 8th, 1:30PM-5:00PM (Poster no. 3460) #AACR24

Rohit Thummalapalli Elad Ziv Adam J. Schoenfeld Dr. Melinda Aldrich, MPH, PhD Christine Lovly, MD, PhD

Happy to share our paper. Great collaboration with star team. Congrats to all! Pooja Middha Linda Kachuri Elad Ziv Christine Lovly, MD, PhD VUMC Department of Medicine Vanderbilt Genetics Institute

Kicking off #AACR24 today walking and learning about #lungcancer screening from expert, colleague, + dear friend Dr. Melinda Aldrich, MPH, PhD. Dr. Aldrich’s work has transformed lung cancer screening. Give her a follow of you haven’t already! AACR #runners4research Vanderbilt-Ingram Cancer Center

⁦Allison Betof Warner, MD, PhD⁩ highlighting future strategies including Obsidian’s engineering of TILs with acrtazolamide-modified membrane bound IL-15 signaling that might obviate need for toxic IL-2 therapy following TIL infusion in #melanoma and other cancers. #immunotherapy

Allison Betof Warner, MD, PhD highlighting work by Adam J. Schoenfeld at Memorial Sloan Kettering Cancer Center showing early potential for experimental #TIL therapy for NSC #lungcancer .

Early days—lots of opportunity to improve strategies to better approach results of #tcellrx in blood cancers.

Important proof of concept for this cell therapy for patients with lung cancer

Promising signals for #TIL in #NSCLC . Proud of you Adam J. Schoenfeld and colleagues!!

Excited to see our phase 2 multicenter study of Tumor-Infiltrating Lymphocyte in Advanced #LungCancer Resistant to Immunotherapy in Cancer Discovery. #TIL #Celltherapy aacrjournals.org/cancerdiscover…

Online now in Cancer Discovery: Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell #LungCancer Resistant to Immune Checkpoint Inhibitors Adam J. Schoenfeld, Kai He & colleagues Memorial Sloan Kettering Cancer Center The James doi.org/10.1158/2159-8…

If you like to read final versions - this was just posted:
Commentary on SMARCA4-deficient undifferentiated tumors mimicking small cell carcinoma.
doi.org/10.1158/1078-0…
Original paper by Sutherland Lab and Jin Ng, PhD
doi.org/10.1158/1078-0…

🚨Just published: The registration enabling clinical data set for an affinity-enhanced TCR targeting the cancer-germline antigen MAGE-4. Afami cell on track to be the *first* FDA approved TCR gene therapy and first gene therapy product for a solid cancer.

thelancet.com/journals/lance…

The registrational enabling Spearhead-1 study shows that afami-cel, an engineered T cell targeting MAGEA4, has promising efficacy in synovial sarcoma and MRCLS paving the way for T cell therapy in solid tumors. Memorial Sloan Kettering Cancer Center MSK Department of Medicine Sarcoma Service at Memorial Sloan Kettering
sciencedirect.com/science/articl…

Thrilled to see our work on genetic prediction of immune checkpoint inhibitor-mediated colitis published in Nature Communications
Elad Ziv Rohit Thummalapalli Dr. Melinda Aldrich, MPH, PhD Linda Kachuri

nature.com/articles/s4146…

Great collaboration between our group Memorial Sloan Kettering Cancer Center Adam J. Schoenfeld, UCSF team Pooja Middha Elad Ziv, and many others - looking forward to further characterizing germline predictors of irAEs!